evaluate the pharmaceuticals and biotechnology company pfizer on top glp-1's Robust Phase IIb for Pfizer's GLP-1 RA berobenatide Pfizer Reports Strong Berobenatide Phase

Emerging approaches, such as antioxidants, NMDA receptor modulators, and cognitive rehabilitation, show promise but require further validation

10.1007/s40272-015-0140-6 27

Each patient underwent a median nerve conduction study, the Boston Carpal Tunnel Questionnaire (BCTQ) and the Neuropathic Pain Symptom Inventory (NPSI)

Authors relationships and activities SDP declares grants from AstraZeneca and Boehringer Ingelheim, consulting fees from Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Merck Sharpe and Dohme, Novartis Pharmaceuticals, Novo Nordisk and Sanofi, and honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Merck Sharpe and Dohme, Novartis Pharmaceuticals, Novo Nordisk and Sanofi